Endocrine Abstracts

Introduction: SGLT2 inhibitors offer a novel approach to improve glycaemic control in patients with type 2 diabetes through inhibition of renal glucose reabsorption. Phase 3 clinical trials demonstrated consistent glucose lowering effects and weight loss. The objective of our audit was to assess the early effects of treatment with dapagliflozin 10 mg in our clinic population.

Methods: We performed a retrospective audit of clinical parameters in patients (n=36, mean age 55.2 years and diabetes mean duration 9.6 years) who attended our hospital in the previous year over a mean follow-up interval of 144 days (25–359 days). 13 patients were previously treated with dual oral agents and 15 with insulin (16–540 units).

Results: We observed a significant improvement in glycaemic control with an HbA1c fall from 85.6 to 72.9 mmol/mol (P<0.01). This was accompanied by a mean weight loss of 2.7 kg (P<0.01). There was a trend for BP reduction but this was non-significant. No significant correlations were observed between weight loss and other clinical variables. Non-responders were comparable to responders in terms of weight, age, and duration of diabetes. One patient discontinued therapy due to side effects (vulval candidiasis). Improvements in glycaemic control allowed for withdrawal of other agents in three patients including withdrawal of prandial insulin in one individual.

Conclusion: In conclusion, this audit of our early experience with the SGLT2 inhibitor dapagliflozin highlighted clinically meaningful improvements in parameters of glycaemic control, weight, and BMI. Long-term follow up for evidence of sustained drug efficacy in clinical practice is awaited.